STRAKAN INTERNATIONAL LIMITED – Trademark Portfolio
Entity Type: 99
STRAKAN INTERNATIONAL LIMITED holds 33 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 33 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include RECTIV, ABSTRAL, and SANCUSO. The owner is based in HAMILTON HM11.
THE PENTHOUSE, WASHINGTON MALL, 1
CHURCH, STREET
HAMILTON HM11 , BM
Showing of trademarks Trademarks
Trademark Classifications
STRAKAN INTERNATIONAL LIMITED's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does STRAKAN INTERNATIONAL LIMITED have?
STRAKAN INTERNATIONAL LIMITED has 33 U.S. trademarks filed with the USPTO. Of these, 3 registered, 9 abandoned, 13 cancelled.
What trademark classes does STRAKAN INTERNATIONAL LIMITED file in?
STRAKAN INTERNATIONAL LIMITED files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are STRAKAN INTERNATIONAL LIMITED's most well-known trademarks?
STRAKAN INTERNATIONAL LIMITED's registered trademark portfolio includes well-known marks such as RECTIV, ABSTRAL, and SANCUSO. These are among 3 currently registered trademarks in the portfolio.
What is STRAKAN INTERNATIONAL LIMITED's trademark registration success rate?
STRAKAN INTERNATIONAL LIMITED has a 12% trademark registration rate, with 3 out of 25 resolved applications resulting in successful registration. Currently, 0 applications are pending review.